May 13, 2025
A blood-based biomarker assay for multiple sclerosis (MS) disease activity provides actionable insights that supplement standard MS evaluations, especially for treatment initiation and de-escalation decisions, a […]
May 13, 2025
TOPLINE: Fremanezumab was associated with a significantly greater reduction in monthly migraine days and symptoms of depression than placebo in patients with migraine and comorbid major […]
May 13, 2025
The clinical utility of the calcitonin gene–related peptide (CGRP) receptor antagonist ubrogepant may extend beyond the treatment of acute migraine to alleviating common prodromal symptoms of […]
May 12, 2025
TOPLINE: Perioperative discontinuation of acetylsalicylic acid (ASA) treatment for 12 days was not associated with a reduction in 6-month recurrence of chronic subdural hematoma (cSDH) in […]
May 9, 2025
Living within a mile of a golf course is associated with a 126% increased risk for Parkinson’s disease (PD), possibly due to increased pesticide exposure, results […]
May 9, 2025
Learning about one’s Alzheimer’s disease (AD) risk may not cause emotional distress — but it could curb motivation to adopt or maintain healthy habits to preserve […]
May 8, 2025
High intake of packaged snacks, hot dogs, sugary sodas, and other ultraprocessed foods (UPFs) was linked to increased risk for early, nonmotor signs of Parkinson’s disease […]
May 5, 2025
The US Food and Drug Administration (FDA) has approved dihydroergotamine (DHE) nasal powder (Atzumi, Satsuma Pharmaceuticals Inc) for the acute treatment of migraine with or without […]
May 1, 2025
SAN DIEGO — Certain musical elements within songs — especially when tied to emotional memories — may trigger a rare form of epilepsy known as musicogenic […]